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on-small cell lung carcinoma
a  b  s  t  r  a  c  t
Rationale:  Clusterin  expression  may  change  in  various  human  malignancies,  including  lung cancer.
Patients  with  resectable  non-small  cell  lung  cancer  (NSCLC),  including  adenocarcinoma,  have a  poor
prognosis,  with  a  relapse  rate  of  30–50%  within  5 years.  Nuclear  factor  kB  (Nf-kB)  is an  intracellular
protein  involved  in  the  initiation  and  progression  of several  human  cancers,  including  the  lung.
Objectives:  We  investigate  the  role  of clusterin  and  Nf-kB  expression  in predicting  the  prognosis  of patients
with  early-stage  surgically  resected  adenocarcinoma  of  the  lung.
Findings:  The  level  of clusterin  gradually  decreased  from  well-differentiated  to  poorly  differentiated
adenocarcinomas.  Clusterin  expression  was  significantly  higher  in patients  with  low-grade  adenocar-
cinoma,  in  early-stage  disease  and  in women.  Clusterin  expression  was  inversely  related  to  relapse  andmmunohistochemistry
elapse
urvival
survival in  both  univariate  and  multivariate  analyses.  Finally,  we  observed  an  inverse  correlation  between
Nf-kB and  clusterin.
Conclusions:  Clusterin  expression  represents  an  independent  prognostic  factor  in  surgically  resected  lung
adenocarcinoma  and  was  proven  to  be  a useful  biomarker  for  fewer  relapses  and  longer  survival  in
patients  in  the  early  stage  of  disease.  The  inverse  correlation  between  Nf-kB  and  clusterin  expression
confirm  the  previously  reported  role  of  clusterin  as  potent  down  regulator  of  Nf-kB.. Introduction
Lung cancer is the leading cause of cancer-related mortality.
espite major advances in treatment, the prognosis for patients
ith lung cancer has not significantly improved in the last 2 decades
1]. When identified at an early stage, lung adenocarcinoma is pri-
arily treated by surgical resection, which is potentially curative.
owever, 30–60% of patients with stage IB to IIIA non-small cell
ung cancer (NSCLC) die within 5 years after surgery, primarily
rom recurrence of the tumor [2].  Therefore, although TNM stag-
ng is the established prognostic indicator, better parameters are
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urgently needed for more accurate prediction of the outcome and
more precise indication of the efficacy of treatment.
Clusterin (CLU, also known as ApoJ) is a heterodimeric glycopro-
tein, expressed in all tissues and found in all human fluids, including
the lung, suggesting that this protein performs functions of funda-
mental importance both inside and outside the cell. Indeed, CLU has
been found to be involved in various physiologic processes impor-
tant for carcinogenesis and tumor growth, including apoptotic cell
death, cell cycle regulation, DNA repair, tissue remodeling, lipid
transportation, membrane recycling, and immune system regula-
tion [3–5]. Several studies have examined the prognostic value of
CLU in various malignancies, with conflicting results [6–9]. Only
one study investigated the prognostic role of CLU in a heteroge-
neous series of resected NSCLC, and the results suggested that CLU
expression could be a positive prognostic indicator for NSCLC [10].Nf-kB is a transcription factor associated with the initiation
and progression of several human tumors, including lung cancer
[11] and is considered a potentially oncogenic transcription fac-
























































BAC component and 41.09 ± 62.79 (median 9, range 0–270). Nf-
kB immunostaining was  considered positive in 48 patients (57.8%).F. Panico et al. / Lung
everal in vitro studies demonstrated that Nf-kB activation is
nhibited by CLU [13,14] and that the deletion of CLU induces acti-
ation of Nf-kB [15] suggesting an interrelationship between these
 proteins.
The aim of the present study was to investigate the level
f expression and the prognostic role of CLU, in terms of both
verall survival and disease-free survival, in a well-defined pop-
lation of patients with early-stage (stages I and II), surgically
esected adenocarcinoma of the lung. Furthermore, we analyzed
he relationship between CLU and Nf-kB expression and various
linical–pathological features in the same cohort of patients.
. Methods
.1. Patients
Files from the archives of the Section of Pathology and of
he Division of Thoracic Surgery of the University of Modena
nd Reggio Emilia were retrospectively reviewed to retrieve
ll patients with a definitive diagnosis of non-small cell lung
arcinoma (NSCLC) who  underwent a radical surgical resection
etween January 2000 and December 2004. All the pathological
lides were reviewed by one pathologist (G.R.) and reclassified
ccording to the criteria set by the 2004 WHO  lung tumors clas-
ification. In fact, this study was performed prior the publication of
he current consensus paper [16].
Only caucasian patients with definitive diagnosis of primitive
denocarcinoma of the lung and a complete resection (R0 resection)
ere included; patients with other known primary tumors and a
inor or incomplete resection (R1 or R2 resection) were excluded
rom the study. Only early stages of disease (Stage I and Stage II
ccording to the 1997 IASLC/UICC TNM staging system for lung
umors) were considered. Eighty-three patients met  all criteria and
ere enrolled in the study.
The percentage of bronchioloalveolar component (BAC) (as a
on-replacing type adenocarcinoma according to the 2004-WHO
lassification) was assessed in all patients. BAC percentage was
easured by counting the BAC ratio for each slide under ocular
eld with grid (100 grids per field) and averaging the BAC compo-
ent across slides. The process was repeated twice for each slide,
nd the final average was  used as the percentage of BAC for a given
umor case.
.2. Immunostaining correlations
In each case, 3-m thick sections were obtained from a rep-
esentative block. Sections were air-dried overnight at 37 ◦C, then
eparaffinized in xylene and rehydrated through a decreasing con-
entration of alcohol to water. Endogenous peroxidase activity
as blocked by immersion for 10 min  in 3% hydrogen per-
xide (H2O2) in methanol. Incubation with primary antibody
CLU, clone 41D, Upstate Biotechnologies, Lake Placid, NY; 1.200
ilution; microwave antigen retrieval) was accomplished with
 modified streptavidin–biotin–peroxidase technique using an
utomated immunostainer (Benchmark, Ventana, Tucson, AZ); 3′-
-diaminobenzidine was used as the chromogene and Harris’s
ematoxylin as the counterstain. Negative and positive controls
ere included in each batch. Phospho-Nf-kB p65 Ser536, (93H1)
Cell Signaling 1:200) was used for Nf-kB staining, under the same
onditions. Percentage of positive cells and staining intensity (neg-
tive = 0, weak = 1, moderate = 2, strong = 3) were evaluated and
ultiplied to render the staining score (CLU staining index and Nf-
B staining index). In order to find the value of CLU staining index
ith the best accuracy in predicting prognosis, we  performed ar 79 (2013) 294– 299 295
Receiver Operating Characteristic (ROC) analysis for the CLU stain-
ing index in predicting recurrence after surgical resection (Fig. 1).
The value of 40 was  associated to the cut-off value. In further
survival analysis and CLU correlation, we  considered a CLU staining
index more than 40 as definitively positive and a value of Nf-kB
staining index higher than 0 as definitively positive.
2.3. Follow-up
Most patients were followed directly at the Division of Thoracic
Surgery and Division of Respiratory Diseases of the University of
Modena and Reggio Emilia with periodic office visits. Information
about the remaining patients was obtained from the Oncologic
Institutes treating them or by telephone interviews with the
patient and/or his/her relatives. Data regarding long-term sur-
vival, presence and type of recurrence were recorded. We  assigned
a patient to “recurrent disease” only after histological confirma-
tion, except for obvious clinical situations (widespread multiple
lesions).
2.4. Statistical analysis
The descriptive analysis was  expressed in terms of frequency,
mean, median and standard deviation. Frequencies were compared
with the chi-square test for categorical variables; Fischer’s exact
test was  used for small samples. T-test and ANOVA were performed
when comparing continuous variables. Correlation between CLU
staining index and other quantitative variables was investigated
with the Pearson’s correlation coefficient; the goodness-of-fit mea-
sure of each linear model (R2) were reported. Correlation between
CLU staining index and Nf-kB staining index was investigated with
the Spearman’s rank correlation coefficient. Overall survival (OS)
was  calculated from the date of surgical resection to the date of
death or last follow-up. Disease-free survival (DFS) was calculated
from the date of surgical resection to the date of recurrence. The OS
and DFS were calculated according to the Kaplan–Meier method.
Overall Survival (OS) and DFS rates at 5 years were chosen as end
points for evaluating the prognosis. Univariate analysis for any
potential prognostic factor was performed using the Log-Rank test.
A Cox proportional hazards model was fitted to estimate hazard
ratios and confidence intervals for those prognostic factors signifi-
cant in univariate analysis. A probability value (P) was considered
statistically significant when <0.05; all P values were based on two-
sided tests.
3. Results
The resected tumors of 83 caucasian patients with pulmonary
adenocarcinoma who  underwent radical resection were analyzed
for CLU and Nf-kB expression.
The clinicopathologic characteristics of the patients are reported
in Table 1. Mean age for all patients was 66.0 ± 9.1 years
(range 36–84). The mean smoking index was  20.2 pack/years
(range 0–60).
CLU immunostaining was  considered positive in 63 patients
(76%). The mean CLU staining index was  170 ± 91.8 (median 140,
range 50–270) for patient with BAC, 97.64 ± 77.9 (median 70,
range 0–270) for patients with adenocarcinoma with a variableThe mean Nf-kB staining index was 3 ± 6.7 (median 0, range 0–15)
for patient with BAC, 13.52 ± 38.85 (median 0, range 0–135) for
patients with adenocarcinoma with a variable BAC component and
36.43 ± 44.29 (median 20, range 0–210).
296 F. Panico et al. / Lung Cancer 79 (2013) 294– 299

















ig. 1. Receiver operating characteristic (ROC) analysis and interactive dot diagram
oint  to differentiate patients who experience recurrence after surgical resection (v
.1. CLU immunostaining correlations
The correlations between immunohistochemical expression of
LU and Nf-kB with clinical–pathological variables are reported in
able 2.
A significant association was noted between CLU expression
nd sex (P = 0.024), histological grading (P < 0.001), presence of BAC
omponent (P = 0.002) and pathologic stage (P = 0.016). CLU was
xpressed significantly more often in women, although smoking
abit and age were not statistically significant between males and
emales, in low-grade adenocarcinoma and in early stages of can-
er progression. In particular, all pure BAC tumors significantly
xpressed CLU, whereas poorly differentiated adenocarcinomas
requently did not express CLU.
Nf-kB was significantly more expressed in high-grade (P = 0.034)
nd invasive adenocarcinomas without BAC component (P = 0.028).


























With BAC component 13 (18)
Other mixed 4 (4)
Papillar 8 (10)
Solid with mucin production 8 (10)
Mucinous “colloid 3 (3)
Signet ring 2 (2)
Fetal type 2 (2)
Clear cell 1 (1)
Pure BAC 4 (4)he CLU staining index in relation to recurrence. The value of 40 is the ideal cutoff
) from patients who remain free of disease (value 0).
between CLU and Nf-kB expression: high levels of CLU expression
were associated with low levels of Nf-kB expression (Spearman’s
rho = −0.4282, P = 0.0001) (Fig. 2).
To better clarify which clinical-pathologic parameters signif-
icantly correlated with CLU expression, we  also performed a
bivariate statistical analysis. Tumors that expressed a BAC compo-
nent (pure BAC, and mixed adenocarcinoma with BAC component)
were correlated with CLU staining index, and a highly signifi-
cant linear correlation with the percentage of BAC component was
found. The CLU staining index increased significantly with the per-
centage of BAC component (Pearson correlation coefficient 0.726;
R2 = 0.527; P = 0.001).
In the whole series, an inverse linear correlation between CLU
and smoking index approached significance (Pearson correlation
coefficient −0.215; R2 = 0.046; P = 0.067). Conversely, no signifi-
cant correlation was found between the CLU staining index and
age (Pearson correlation coefficient −0.086; R2 = 0.007; P = 0.440)
or tumor size (Pearson correlation coefficient −0.025; R2 = 0.001;
P = 0.823).
3.2. Analysis of survival
Follow-up was  discontinued for all patients in July 2008. Median
follow-up was  44.5 months (3.7 years) (range 1–97 months). Over-
all 5-year survival rate was 50% with a median survival time of 61
months. Eight deaths were not cancer related; 33 patients died of
the disease. The rate of DFS was 48% with a median disease-free sur-
vival time of 55 months. The tumors recurred in 38 patients (47.4%):
13 patients with intrathoracic recurrence and 25 patients with sys-
temic dissemination. Six patients were alive with recurrent disease
at the end of follow-up. A significant correlation was found between
the crude recurrence rate and the CLU staining index: 29.4% for
positive CLU expression and 59.2% for negative CLU expression;
P = 0.008.
Results of univariate analysis regarding OS and DFS for the
clinicopathologic prognostic factors are shown in Table 3. Stage,
grading, and CLU staining index predicted both OS and DFS, while
sex predicted only overall survival. Nf-kB staining index did not
predict OS neither DFS. Regarding the CLU staining index, univari-
ate survival analysis showed a 5-year OS rate of 72% for patients
with positive CLU expression and 35% for patients with negative
CLU expression (log rank 9.92; P = 0.001) and a 5-year DFS rate of
67% for patients with positive CLU expression and 34% for patients
with negative CLU expression (log rank 8.49; P = 0.003).
When we  stratified the analysis of survival by pathologic stage,
the CLU staining index remained a significant prognostic factor
even at early stages (IA and IB): a 5-year OS rate of 73% for



















ig. 2. Hematoxylin–eosin staining, clusterin staining and Nf-kB staining in a pure
denocarcinoma (B, E and H, respectively) and in partial colonization of a norma
espectively).
LU-positive patients vs. 42% for CLU-negative patients (P = 0.016),
nd a 5-year DFS rate of 66% for CLU-positive patients vs. 39% for
LU-negative patients (P = 0.021).
To evaluate the independent prognostic value of CLU expression,
e performed a multivariate analysis using the Cox proportional
azards model with the variables significantly related to survival
y univariate analysis (Table 4). The CLU staining index was found
o be the only independent factor predicting recurrence, whereas
athologic stage was the only prognostic factor significantly associ-
ted with OS. A positive CLU staining index score was significantly
ssociated with longer DFS (P = 0.048); the association with OS
pproached statistical significance (P = 0.052). Adenocarcinomas
ith a negative CLU staining index score had a relative risk of
able 2
ssociation between clusterin staining index and Nf-kB staining index and clinicopatholo
Variable Clusterin staining P 
Positivea Negativea
Sex
Male 21 (34%) 41 (66%) 0.0
Female 13 (62%) 8 (38%) 
Grading
G1  10 (83%) 2 (17%) 0.0
G2  11 (55%) 9 (45%) 
G3 13  (25%) 38 (75%) 
Histological subtype
BAC 4 (100%) 0 0.0
ADK-BAC 9 (69%) 4 (31%) 
Other  subtypes 21 (32%) 45 (68%) 
Pathologic stage
IA + IB 32 (47%) 36 (53%) 0.0
IIA  + IIB 2 (13%) 13 (87%) 
bbreviation: ADK-BAC, adenocarcinoma with BAC component.
a Raw percentages.inous-type bronchioloalveolar carcinoma (A, D and G, respectively), in a papillary
nchiole by 2 foci of well-differentiated adenocarcinoma (see arrows) (C, F and I,
recurrence of 2.18 (95% confidence interval 1.00–4.75) compared to
CLU-positive tumors; patients with adenocarcinoma had a relative
risk of death of 2.39 (95% confidence interval 0.99–5.77). Early-
stage disease (IA and IB) predicted greater survival than stage II
disease (P = 0.02). Neither tumor differentiation nor sex had any
significant association with death or recurrence in multivariate
analysis.
4. DiscussionTo our knowledge, this is the first study exploring in vivo the





24 37 (60%) 25 (40%) 0.615
11 (52%) 10 (48%)
01 4 (%) 8 (%) 0.034
9 (%) 11 (%)
35 (%) 16 (%)
02 1 (25%) 3 (75%) 0.028
4 (31%) 9 (69%)
43 (65%) 23 (35%)
16 40 (83%) 8 (17%) 0.776
8 (53%) 7 (47%)
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Table 3
Results of univariate analysis of overall survival and disease-free survival.
Variable Overall survival Disease-free survival
5 years (%) P value 5 years (%) P value
Sex
Male 42 0.013 42 0.118
Female 71 62
Grading
G1 83 0.026 90 0.016
G2  58 54
G3  37 35
Histological subtype
BAC + ADK-BAC 57 0.158 61 0.159
Other subtypes 45 45
Pathologic stage 0.001 76
IA  79 36 0.024
IB 42  21
IIA  + IIB 28
CLU staining index
Positive 72 0.001 67 0.003
Negative 35 34
NFKB staining index






























bbreviation: ADK-BAC, adenocarcinoma with BAC component.
Our data suggest that CLU expression is an independent pro-
nostic factor in surgically resected adenocarcinoma of the lung.
ultivariate analysis showed that low CLU expression is signifi-
antly related to a high rate of recurrence and death after surgical
esection. Given the established prognostic role of pathologic stage
n lung cancer, we also performed a subgroup analysis stratified
or disease stage: patients with stage I disease who  had high lev-
ls of CLU expression showed significantly higher OS and DFS
ith respect to patients with the same stage with low levels of
LU.
The highly significant inverse correlation found between CLU
nd Nf-kB expression is consistent with what is already known
bout the inhibitory activity of CLU on Nf-kB activity and expression
15]. However, although Nf-kB is known to be involved in initiation
nd cancer progression, there are no studies showing a correlation
etween Nf-kB and cancer OS and DFS.
In a recent study, Dimitrakopoulos and colleagues showed that
ytoplasmic immunoreactivity of NF-B2 and RelB was correlated
ith tumor stage. In addition, cytoplasmic NF-B2 levels were also
elated to tumor grade and expression of RelB in the cytoplasm
as tumor histologic type-specific, with squamous cell carcinomas
aving the highest protein levels [17]. In contrast, in our study CLU
erves as a biomarker for OS and DFS.
Similar findings were reported by Albert et al., who investi-
ated CLU expression levels in patients with different histologic
ypes of NSCLC [10]. In contrast, we focused our study on early-
tage (stages I and II) adenocarcinoma in order to investigate the
ossible involvement of CLU in early stages of cancer progression.
able 4
esults of multivariate analysis (Cox proportional Hazard Models).
Variable Death 
HR (95% CI) 
CLU
Negative vs. positive 2.39 (0.99–5.77) 
Grading
G3  vs. G1 + G2 1.40 (0.64–3.07) 
Pathologic stage
IIA + IIB vs. IA + IB 2.26 (1.10–4.65) 
Sex
Male  vs. female 2.02 (0.92–4.40) 
bbreviations: HR, hazard ratio; CI, confidence interval.r 79 (2013) 294– 299
In addition, this is the only histologic type of lung cancer whose
incidence is increasing, according to epidemiological studies [18].
Moreover, our series included a select group of patients who  were
racially homogeneous, being all caucasian, because of the different
characteristics of adenocarcinomas [19].
The prognostic and predictive [20] value of CLU has already
been evaluated in various malignancies, but conflicting results have
been reported [6–9,21–24].  Conflicting data on the levels of CLU in
lung cancer have also been found. In vitro and in vivo studies have
reported the presence of high levels of CLU in lung cancer cells
[25]. However, data available on the Oncomine database showed
that CLU was  downregulated in tumors as compared to normal lung
(www.oncomine.org). Downregulation of CLU, and a further reduc-
tion of its expression during cancer progression, can also be gleaned
from the results of the present study. CLU expression significantly
decreased from well-differentiated to poorly differentiated adeno-
carcinoma, and from stage I to stage II. This data and the survival
analyses confirm the positive prognostic role of CLU in lung adeno-
carcinoma. The earlier findings of high levels of CLU in lung cancer
cells [25] is not contradictory with our experimental data, because
CLU was  indeed positively expressed in 41% of adenocarcinomas
from our select population.
Here we  investigated for the first time the correlation between
CLU expression and adenocarcinoma subtypes, in particular those
that express a BAC component. We  found BAC in only four patients
(4.8%). However, up to 20% of invasive adenocarcinomas of the lung
showed a mixed pattern, ranging from predominant BAC with a
small focus of invasion, to invasive adenocarcinoma with an iso-
lated group of cells with BAC features [18,26]. In our series, mixed
adenocarcinomas with a BAC component accounted for 16% of all
adenocarcinomas. In cases with pure BAC, CLU was expressed at
high levels, whereas only 30% of cases of invasive adenocarcinoma
expressed high levels of CLU. In mixed adenocarcinomas, with a
variable amount of BAC component, CLU expression was  interme-
diate, being present in 69% of cases; furthermore, CLU expression
was  directly related to the amount of BAC component, decreasing
with the increased invasiveness of the lesions. The molecular events
that regulate the multistep carcinogenesis – hypothesized in lung
adenocarcinoma – are currently unknown, but multiple pathways
and genetic changes are certainly implicated [27–31]. The progres-
sive decrease of CLU expression is clearly one of the molecular
changes implicated in the progression from pure BAC to invasive
adenocarcinoma, and confirm the possible role of CLU as a tumor
suppressor factor against infiltration or invasiveness. In fact, CLU
has been already found as an important regulator of cell fate, neg-
atively controlling further progression and invasiveness [12,32].
Tang et al. [11] showed that Nf-kB expression is an early and fre-
quent feature of lung cancer. Furthermore, Nf-kB expression level
was  significantly higher in advanced adenocarcinomas of the lung
compared to earlier stages [12].
Inverse linear correlation of CLU and Nf-kB expression is consis-
tent with in vitro studies demonstrating and important regulatory
Recurrence
P value HR (95% CI) P value
0.052 2.18 (1.00–4.75) 0.048
0.393 1.59 (0.73–3.48) 0.237
0.026 1.19 (0.52–2.68) 0.675
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oop between these two genes, i.e. while CLU is one of the most
ighly regulated gene by Nf-kB, CLU also regulates Nf-kB activity
n a negative manner by stabilizing I-kBs. These data led to the
ypothesis that CLU participates in a negative loop in which trans-
riptional activation of CLU is evoked to dampen Nf-kB activity
14].
In conclusion, CLU expression is an independent positive pro-
nostic factor in surgically resected adenocarcinoma of the lung.
LU expression could therefore be used as a novel biomarker for
dentifying patients with stage IB adenocarcinoma who require
hemotherapeutic treatment after surgical resection. The pro-
ressive decrease in CLU expression from well-differentiated to
oorly differentiated adenocarcinomas, along with the oncogenetic
rogression from pure BAC, to mixed adenocarcinoma with BAC
omponent, to invasive carcinoma, confirm a positive prognostic
ole for CLU in patients with lung adenocarcinoma. Finally, we
bserved an inverse correlation between Nf-kB and CLU, thus pro-
iding new insights into the potential role in pathogenesis of these
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